Eli Lilly's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Eli Lilly (LLY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Eli Lilly vs Its Competitors
- TTM: Trailing 12-month revenue of 86,462M vs 477,406M combined for its competitors (15.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+12.9% annualized vs trailing 12 months), vs accelerating (+6.2%) for its tracked peer group.
- Growth: Eli Lilly generated 38.6% revenue growth year over year in Q3 2026, vs 7.1% for its competitors combined.
- Profitability: Its 26.4% net margin compares with 15.2% for the peer group.
- Scale: Eli Lilly ranks #1 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 20.7% of industry market cap.
- Peer revenue share: Eli Lilly accounted for 16.2% of combined revenue among its tracked peer group, up from 13.0% a year earlier.
- Peer differentiation: Revenue per employee of $1.73M compares with $0.93M for the peer group (1.9x).
- Structure: Eli Lilly operates in the following segments: Reportable; and reports the following subsidiaries: Adverum Biotechnologies Inc (competes with Kodiak Sciences Inc , Outlook Therapeutics Inc , Peak Bio Inc ), Verve Therapeutics Inc (competes with Editas Medicine Inc , Intellia Therapeutics Inc , Prime Medicine Inc ).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LLY Sales vs. its Competitors, Q3 2026
Eli Lilly reported revenue growth of 38.61 % year on year in Q3 2026, above its competitors' combined revenue growth of 7.14 %.
With a net margin of 26.44 %, Eli Lilly achieved higher profitability than its competitors (15.15 %).
Eli Lilly generated 16.15 % of the combined sales of its peer group, up from 12.96 % a year earlier.
API endpoints for this dataset
Eli Lilly vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Eli Lilly reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Eli Lilly and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Eli Lilly And Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (37) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Eli Lilly's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 38.6% for Eli Lilly. Eli Lilly's share of combined industry revenue moved from 3.66% to 4.66%, a gain of 1.00 percentage points.
Eli Lilly's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Eli Lilly And Company | Yes | Yes | Yes | No |
| Competitors combined (196) | ||||
| High-Confidence Competitors (107) | ||||
| Similar-Size Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LLY Stock Performance relative to its Competitors
LLY Stock Performance relative to High-Confidence Competitors
LLY Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Climb Bio Inc | 282.9% | Outperformed |
| 3 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | Damora Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Eli Lilly's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Eli Lilly's Comment on Competition and Industry Peers
Our human pharmaceutical products compete globally with products of many other
companies in highly competitive markets. Our animal health products compete
globally with products of animal health care companies as well as pharmaceutical,
chemical, and other companies that operate animal health businesses.
Important competitive factors for both human pharmaceutical and animal health
products include effectiveness, safety, and ease of use; price and demonstrated
cost-effectiveness; marketing effectiveness; and research and development of
new products and processes. Most new products that we introduce must compete
with other branded or generic products already on the market or products that
are later developed by competitors. If competitors introduce new products or
delivery systems with therapeutic or cost advantages, our products can be subject
to decreased sales, progressive price reductions, or both.
We believe our long-term competitive success depends upon discovering and developing
(either alone or in collaboration with others) or acquiring innovative, cost-effective
human pharmaceutical and animal health products that provide improved outcomes
and deliver value to payers, together with our ability to continuously improve
the productivity of our operations in a highly competitive environment. There
can be no assurance that our research and development efforts will result in
commercially successful products, and it is possible that our products will
become uncompetitive from time to time as a result of products developed by
our competitors.
Generic Pharmaceuticals
One of the biggest competitive challenges we face is from generic pharmaceuticals.
In the U.S. and the EU, the regulatory approval process for human pharmaceuticals
(other than biological products (biologics)) exempts generics from costly and
time-consuming clinical trials to demonstrate their safety and efficacy, allowing
generic manufacturers to rely on the safety and efficacy of the innovator product.
Therefore, generic manufacturers generally invest far less than we do in research
and development and can price their products much lower than our branded products.
Accordingly, when a branded non-biologic human pharmaceutical loses its market
exclusivity, it normally faces intense price competition from generic forms
of the product. In many countries outside the U.S., intellectual property protection
is weak and we must compete with generic or counterfeit versions of our products.
Many of our animal health products also compete with generics.
Publicly Traded Peers of Eli Lilly And Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Procter and Gamble Co |
398,150.88 | 87,922.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
| SUBTOTAL | 6,345,575.95 | 1,010,040.19 |
Sign in to see all competitors of Eli Lilly And Company.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Eli Lilly And Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Eli Lilly's Competitors Named by the Company
Competitive relationships identified from Eli Lilly reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Denali Therapeutics Inc | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Nyxoah Sa | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Innate Pharma Sa | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Novo Nordisk A | Company report | 85% |
| Opthea | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Outlook Therapeutics | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Ocular Therapeutix | Company report | 85% |
| REGENXBIO | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Kodiak Sciences | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Point Pharmaceuticals | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Opus Genetics Inc | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| OCUP | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Xeris Biopharma Holdings Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Graybug Vision | Company report | 85% |
| Janssen | Company report | 85% |
| Inflarx N V | Company report | 85% |
| 4D Molecular Therapeutics | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Hoffmann-La Roche Ltd. | Company report | 85% |
| UCB | Company report | 85% |
| Bayer | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Scholar Rock | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Fresh Tracks Therapeutics Inc | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Generic Pharmaceuticals | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Precision Biosciences Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Organon and Co | Company report | 85% |
Company report basis, confidence, active dates and source counts for Eli Lilly's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Eli Lilly's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Procter and Gamble Co | Fabric & Home Care 35.25 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Procter and Gamble Co | 398,151 | 845,404 | 154,750 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| PEERS TOTAL | 5,135,912 | 933,094 | 120,234 |
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Procter and Gamble Co | Non-US 52.05 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Eli Lilly's industry classification, broader than the peer set above. Market cap in millions of $.Eli Lilly ranks #1 of 495 companies by market capitalization in its industry, holding 20.69 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
Market cap and industry share for the rest of Eli Lilly's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Eli Lilly's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 46.61 % |
| 2 | Johnson and Johnson | 674,004 | 43.67 % |
| 3 | Beone Medicines Ltd | 1,234 | 12.3% |
| 4 | Abbvie Inc | 1,234 | 12.3% |
| 5 | Merck and Co Inc | 1,234 | 12.3% |
| 6 | Novartis Ag | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Eli Lilly's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Eli Lilly's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.63 % | 37.89 % (avg) | +45.7 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 43.55 % | -6.23 % (avg) | +49.8 pp |
| Capital Intensity (Capex / Revenue) | 12.70 % | 7.58 % (avg) | +5.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Eli Lilly's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 38.3x | 26.6x | +11.7x |
| EV / EBITDA | 29.1x | 15.9x | +13.2x |
| P/B | 32.0x | 4.3x | +27.7x |
| Return on Equity | 83.65 % | industry aggregate | 58.46 % |
| Return on Invested Capital | - | -9.83 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Eli Lilly's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 10.41 % | -11.62 % | 9.95 % | 15.40 % | 0.79 % | 19.56 % | 32.00 % | 44.70 % |
| Operating Margin | 12.21 % | 22.29 % | 24.69 % | 22.45 % | 24.97 % | 30.06 % | 35.92 % | 44.82 % |
| Return on Invested Capital | 6.79 % | 16.57 % | 16.88 % | 15.16 % | 17.27 % | 22.45 % | 27.23 % | 33.80 % |
| P/E | 48.6x | 14.4x | 24.2x | 42.0x | 52.1x | 100.6x | 70.7x | 41.7x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Eli Lilly's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Eli Lilly falls in the Cash Cow quadrant: relative market share of 1.80x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Eli Lilly's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 12.70 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Eli Lilly's dedicated Suppliers and Customers pages, not here.
Eli Lilly's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Eli Lilly falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Eli Lilly's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 495, 20.69 % share).
- Return on equity 58.5 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+12.9% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (47.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Eli Lilly's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Procter and Gamble Co | 0.26 | 0.71 | 0.71 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Eli Lilly And Company.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Eli Lilly's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Procter and Gamble Co | Q3 2026 | +4.0 % | -1.0 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.5 % | +7.1 % |
Sign in to see all peers for Eli Lilly And Company.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Eli Lilly's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Procter and Gamble Co | Q3 2026 | +7.3 % | +13.8 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Eli Lilly And Company.
Eli Lilly's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Procter and Gamble Co | 12.54% | 17.47% | 29.71% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Eli Lilly And Company.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Eli Lilly's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Abbvie Inc | 50.14 | 7.82 |
| Procter and Gamble Co | 25.02 | 4.53 |
| Merck and Co Inc | 118.32 | 5.44 |
| PEERS AVERAGE | 43.29 | 6.28 |
Sign in to see all peers for Eli Lilly And Company.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.